Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 194,905	$ 4,762
Short-term investments	1,140,445	291,370
Accounts receivable	43,213	5,014
Inventory	11,381	10,726
Advance payments to contract manufacturers	26,450	7,155
Other current assets	21,293	7,793
Total current assets	1,437,687	326,820
Long-term investments	582,889	57,088
Property, plant and equipment, net	48,851	47,463
Goodwill	76,501	76,501
Other assets	4,244	994
Total assets	2,150,172	508,866
Current liabilities:
Accounts payable	5,854	4,782
Accrued compensation	9,937	8,263
Accrued contract manufacturing expenses	23,841	3,845
Accrued clinical trial expenses	14,700	9,461
Other accrued expenses	9,087	6,219
Interest payable	4,198	4,198
Deferred revenue, current portion	13,892	18,949
Other current liabilities	493	446
Total current liabilities	82,002	56,163
Senior secured notes, net	246,950	245,207
Liability related to the sale of future royalties, net	82,911	94,655
Deferred revenue, less current portion	10,744	19,021
Other long-term liabilities	9,990	5,992
Total liabilities	432,597	421,038
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2018 or 2017	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 173,530 shares and 159,524 shares issued and outstanding at December 31, 2018 and 2017, respectively	17	15
Capital in excess of par value	3,147,925	2,207,865
Accumulated other comprehensive loss	(6,316)	(2,111)
Accumulated deficit	(1,424,051)	(2,117,941)
Total stockholders’ equity	1,717,575	87,828
Total liabilities and stockholders’ equity	$ 2,150,172	$ 508,866